Effectiveness of rituximab in neuromyelitis optica: a meta-analysis

BACKGROUND: Neuromyelitis optica (NMO) is a severe inflammatory autoimmune disorder of the central nervous system and often results in paralysis or blindness. Rituximab (RTX) is a mouse–human chimeric monoclonal antibody specific for the CD20 antigen on B lymphocytes and used to treat many autoimmun...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Fulin, Chai, Bingyan, Gu, Cheng, Wu, Ruipeng, Dong, Tong, Yao, Yuping, Zhang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402122/
https://www.ncbi.nlm.nih.gov/pubmed/30841862
http://dx.doi.org/10.1186/s12883-019-1261-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402122/
https://www.ncbi.nlm.nih.gov/pubmed/30841862
http://dx.doi.org/10.1186/s12883-019-1261-2

Ejemplares similares